Anaptysbio (ANAB) Non-Current Debt (2016 - 2019)
Anaptysbio (ANAB) posted Non-Current Debt of $3.1 million for Q3 2019, down 35.42% on a QoQ basis from $4.8 million in Q2 2019, and up 28.68% year-over-year from $2.4 million in Q3 2018.
Anaptysbio (ANAB) Non-Current Debt (2016 - 2019) Analysis & Trends
Anaptysbio's Non-Current Debt history runs 4 years deep, the most recent figure standing at $3.1 million for Q3 2019.
- Quarterly Non-Current Debt rose 28.68% year-over-year to $3.1 million in Q3 2019, while the trailing twelve-month figure through Sep 2019 was $3.1 million (up 28.68% YoY) and the FY2018 annual result came in at $625000.0, down 91.73% from the prior year.
- Non-Current Debt was $3.1 million for Q3 2019 at Anaptysbio, down from $4.8 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $13.8 million in Q4 2016 and bottomed at $625000.0 in Q4 2018.
- A 4-year average of $6.8 million and a median of $6.2 million in 2018 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2018 — Non-Current Debt slumped 91.73% — and 2019, when it climbed 28.68%.
- Anaptysbio's Non-Current Debt stood at $13.8 million in 2016, then slumped by 45.3% to $7.6 million in 2017, then slumped by 91.73% to $625000.0 in 2018, then soared by 396.0% to $3.1 million in 2019.
- Business Quant data shows ANAB's Non-Current Debt at $3.1 million in Q3 2019, $4.8 million in Q2 2019, and $6.5 million in Q1 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 105.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 842.92 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Anaptysbio | 1.55 Bn | 1.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 3.10 Mn |
| Jun 30, 2019 | 4.80 Mn |
| Mar 31, 2019 | 6.50 Mn |
| Dec 31, 2018 | 625,000.00 |
| Sep 30, 2018 | 2.41 Mn |
| Jun 30, 2018 | 4.12 Mn |
| Mar 31, 2018 | 5.83 Mn |
| Dec 31, 2017 | 7.55 Mn |
| Sep 30, 2017 | 9.27 Mn |
| Jun 30, 2017 | 10.99 Mn |
| Mar 31, 2017 | 12.71 Mn |
| Dec 31, 2016 | 13.81 Mn |